JPS6341425A - Lubricant external ointment for combined purposes of lubrication in hyposecretion of bartholin's gland and mechanical troubles thereby - Google Patents
Lubricant external ointment for combined purposes of lubrication in hyposecretion of bartholin's gland and mechanical troubles therebyInfo
- Publication number
- JPS6341425A JPS6341425A JP61183425A JP18342586A JPS6341425A JP S6341425 A JPS6341425 A JP S6341425A JP 61183425 A JP61183425 A JP 61183425A JP 18342586 A JP18342586 A JP 18342586A JP S6341425 A JPS6341425 A JP S6341425A
- Authority
- JP
- Japan
- Prior art keywords
- bartholin
- lubrication
- hyposecretion
- gland
- lysozyme chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005461 lubrication Methods 0.000 title abstract description 3
- 210000002947 bartholin's gland Anatomy 0.000 title abstract 2
- 239000000314 lubricant Substances 0.000 title description 3
- 239000002674 ointment Substances 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 8
- 102000016943 Muramidase Human genes 0.000 claims abstract description 8
- 108010014251 Muramidase Proteins 0.000 claims abstract description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 8
- 239000004325 lysozyme Substances 0.000 claims abstract description 8
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 8
- 229960000274 lysozyme Drugs 0.000 claims abstract description 8
- 230000001050 lubricating effect Effects 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 8
- 206010003694 Atrophy Diseases 0.000 abstract description 8
- 230000037444 atrophy Effects 0.000 abstract description 8
- 230000028327 secretion Effects 0.000 abstract description 6
- 230000003340 mental effect Effects 0.000 abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 3
- 230000036506 anxiety Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000003906 humectant Substances 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000008602 contraction Effects 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 210000004999 sex organ Anatomy 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 230000007423 decrease Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 210000003905 vulva Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は外用塗布潤滑液剤に関するもので、これに配合
される成分は1日本薬局法外医薬品、並びに化粧品原料
基準収載品目を使用して調整、生理的に分泌液に類似さ
せ、すぐれた水分の吸蔵効果と湿潤効果を存し、そのゲ
ル状構造により、摩擦抵抗を緩和し1組織を保護する作
用があると同時に障害を起した場合にのみ作用する塩化
リゾチームにより1局部障害の治療をしようとするもの
である。したがって本発明の外用塗布潤滑治療液はこれ
を女性性器に塗布することにより、すべての機械的接触
による障害をなくし又、障害等異状状態の人に対しては
その治療をすることを目的とするものである。。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a lubricating liquid for external use, and the ingredients blended into it are prepared using drugs listed in the Japan Pharmacopoeia's legal standards and items listed in the standards for cosmetic raw materials. Similar to this, it has excellent water absorption and moisturizing effects, and its gel-like structure reduces frictional resistance and protects tissues. At the same time, lysozyme chloride, which acts only when damage occurs, protects tissues. It attempts to treat local disorders. Therefore, the objective of the externally applied lubricating treatment liquid of the present invention is to eliminate all disorders caused by mechanical contact by applying it to the female genitals, and to treat people with abnormal conditions such as disorders. It is something. .
子宮体内膜においては、腺分泌があり、頚管線が粘液を
分泌し頚管を栓塞し1周期的に剥落ず機序がはたらいて
細菌感染のバリヤーとなり、自然に細菌感染の防護作用
が行われている。In the lining of the uterus, there is glandular secretion, and the cervical line secretes mucus that obstructs the cervical canal and does not slough off periodically, functioning as a barrier to bacterial infection and naturally providing protection against bacterial infection. It is being said.
また膣腔には濾出作用があるため常に湿潤しており、帯
下による膣自浄作用がある。これらに由来する液体は通
常は性器管を湿潤する程度の1であって分泌物の変動は
少くて常に調整されている。In addition, the vaginal cavity has a filtration effect, so it is always kept moist, and the vaginal cavity has a self-cleaning effect due to vaginal discharge. The fluid derived from these is usually just enough to moisten the genital tract, and the fluctuations in secretion are small and constantly regulated.
外陰では刺激や心理的影響によって大きい変動を受ける
バルトリン線、スキーン線があり、そのつど分泌され、
外陰部、膣前庭部を湿潤させる。In the vulva, there are Bartholin's lines and Skene's lines, which are subject to large fluctuations due to stimulation and psychological influences, and are secreted each time.
Moisten the vulva and vestibule.
このような生理的現象は、更年期におよんで不規則とな
り。These physiological phenomena become irregular during menopause.
閉経し、特有な症状があられれ、性器の退行がみられる
ようになる。After menopause, specific symptoms occur and genital degeneration is observed.
更年期以降の婦人では、卵巣機能の衰退とともにその機
能活動の失調が起り、性器の萎縮現象があられれてくる
と同時に分泌される液体が減退し、外陰組織においては
全身的な脂肪沈着の減少に伴い、皮脂線の活動も低下し
外陰全体の皮下脂肪も減少し皮下弾力繊維の減少も加わ
り、バルトリン線、スキーン線の分泌機能低下が並行す
る。したがって弾力性を失い弛緩し乾燥して脆弱となり
、外部よりの刺激、外傷、感染に対する組繊抵抗力の減
退が起る。In women after menopause, ovarian function declines and its functional activity becomes impaired, genital atrophy occurs, fluid secreted decreases, and fat deposits in the vulvar tissue decrease throughout the body. Along with this, the activity of the sebaceous glands decreases, the subcutaneous fat of the entire vulva decreases, and the subcutaneous elastic fibers also decrease, which causes a parallel decline in the secretory function of Bartholin's and Skene's lines. As a result, the fibers lose their elasticity, become loose, dry, and brittle, and their resistance to external stimuli, trauma, and infection decreases.
老年期となると外陰組織全体の萎縮性、退縮性変化はさ
らに進行する。また小陰唇も縮小、罪薄化、平面化し、
陰核の縮小も起り、膣人ロ、瞳前庭部は狭小となってく
る。このように萎縮が進行すると同時に湿潤性を失い乾
燥し、性交等機械的行動の接触によって容易に傷害を受
は易くなる。瞳部では閉経後に。In old age, atrophic and degenerative changes in the entire vulvar tissue progress further. The labia minora also shrink, become thinner, and become flatter.
The clitoris also shrinks, and the vagina and vestibule become narrower. As atrophy progresses, the skin loses its wettability and becomes dry, making it easily susceptible to injury from mechanical contact such as sexual intercourse. In the pupil area, after menopause.
粘膜下筋層が萎縮し弾力性の消失が起り、 lta壁の
皺襞が消失し装柱は萎縮し、伸展性を失い平滑でやや硬
くなり、膣腔は混、11A性を失い狭小となってゆく。The submucosal muscle layer atrophies and loses its elasticity, the wrinkles in the lta wall disappear, and the pillars atrophy, losing their elasticity and becoming smooth and slightly hard, and the vaginal cavity loses its mixed, 11A character and becomes narrow. go.
このように膣粘膜上皮の含水性は減少し膣壁からの分泌
物も減少し、pHはやや上昇し粘膜上皮1’JI]抱内
のグリコーゲン含量の減少やそれに伴う乳酸産性の機序
も阻害され、粘膜の罪薄化などに起因するアルカリ性へ
の変化が膣内常在のデーデルライン杆閑を減少させるか
、消滅させて、I111000浄作用が失われ、外部か
ら病原閏の進入を許すことになる。In this way, the water content of the vaginal mucosal epithelium decreases, the secretions from the vaginal wall decrease, the pH increases slightly, and the glycogen content in the mucosal epithelium decreases and the associated lactic acid production mechanism also decreases. The change to alkalinity caused by the thinning of the mucous membrane reduces or eliminates the Daederlein barrier that normally exists in the vagina, and the I111000 purifying action is lost, preventing the entry of pathogens from the outside. I will forgive you.
子宮瞳部では閉経後の加令による萎縮退行の最も著しい
部で。The pupil of the uterus is the area where the atrophy and regression caused by aging after menopause is most pronounced.
瞳部、外陰部に並行して出現し、この部は次第に縮小し
平坦となり、外子宮口ではm管線の粘液分泌もなくなり
、狭小化し。It appears parallel to the pupil and vulva, and this area gradually shrinks and becomes flat, and the external cervix no longer secretes mucus from the m-canal line and becomes narrower.
粘膜上皮も急速に罪薄なものとなり、湿潤性を失い乾燥
するようになる。このため外的な機械的刺激に対し傷害
を受は易(。The mucosal epithelium also rapidly becomes thin, loses its wettability and becomes dry. For this reason, they are easily injured by external mechanical stimuli.
細菌にも感染され易くなる。It also makes you more susceptible to bacterial infections.
一方、近世代に於いては頭脳的労働の過密さにより精神
的過電となり5精神、神経不安症等に起因し1分泌に異
常を起こす人々が増加しつつある。この様な人にとって
も当品は不可欠な価値を有する。On the other hand, in recent generations, an increasing number of people are suffering from mental overload due to overcrowding of mental labor, causing abnormalities in secretion due to mental illness, nervous anxiety, etc. This product has essential value for these people as well.
本発明者らはこのような女性性器の更年期より老年期に
向っての変化と近世代的精神、神経不安に起因する分泌
異常状態を考察し、睡々検討の結果、特に生理的分泌液
の性状に類似し。The present inventors have considered the changes in female genital organs from menopause to old age, and the state of abnormal secretion caused by modern mental and nervous anxiety. Similar in properties.
保水性、湿潤性にすぐれた粘液構造の塗布液をうろこと
に成功し、′!た障害を起した場合にはその治療をも兼
備させることにより本発明を完成した。We succeeded in applying a coating solution with a mucus structure that has excellent water retention and wettability. The present invention has been completed by also providing treatment for other disorders that occur.
本発明のfA!11液を外陰部性女性性器に塗布すると
、外陰部粘膜池萎縮狭小化した部位は保水性、湿潤性に
よって柔軟となり。fA of the present invention! When Liquid 11 is applied to the vulvar female genitalia, the atrophied and narrowed area of the vulvar mucosa becomes flexible due to its water retention and wettability.
萎縮を緩和し、かつ ゲル様の構造により摩擦抵抗を低
下させ。Alleviates atrophy and reduces frictional resistance due to its gel-like structure.
機械的刺激に対する障害が極力排除され且、障害が起き
た場合にはその治療をするものである。なあ、この潤滑
液は細菌感染を予防し、それが物性上パル) IJン線
線分液液類似することで精神的充足感をも与える。この
外用塗布潤滑液剤は従来公知の配合剤である。The goal is to eliminate obstacles to mechanical stimulation as much as possible, and to treat any problems that occur. By the way, this lubricant prevents bacterial infection, and it also gives a sense of mental satisfaction because its physical properties are similar to IJ's line separator liquid. This externally applied lubricating liquid is a conventionally known compound.
抗酸化剤、防腐剤、キレート剤の池増粘剤としてeセル
ローズ系統
・アクリール酸系統
◆ポリビニルアルコール
・ポリビニルピロリドン等合成増粘剤
・ザンサンガム等、天然増粘剤
の何れも使用可能であり、グリセリン、1.3ブチレン
クリコール、プロピングリコール、ポリエチレングリコ
ール等、保湿剤を配合させ、ゼリー状又はペースト状と
し、最終的には乳酸酸性とすることによって得られる。Antioxidants, preservatives, and chelating agents As thickeners, any of e-cellulose type, acrylic acid type, synthetic thickeners such as polyvinyl alcohol and polyvinylpyrrolidone, and natural thickeners such as xanthan gum can be used, and glycerin , 1.3 Butylene glycol, propine glycol, polyethylene glycol, or other moisturizing agent is mixed therein to form a jelly or paste, and the final product is acidified with lactic acid.
55才以降の再婚直後の夫婦10組について当初1m1
1本を外陰部等に塗布し性交等機械的接触に対してテス
トした結果1強度の膣口萎縮狭小等の3組に僅少の出血
を生じた以外は目的を達し、夫婦共に連続使用を強く希
望した。 なお、3組の夫婦は細菌感染は全くなく、連
続使用によって障害も逐次治癒し94人同様に改善され
継続使用を希望した。老令化社会へ向う折柄本発明の外
用塗布潤滑液剤は日常必需品になると思われる。Initially 1m1 for 10 couples who have just remarried after the age of 55
One bottle was applied to the vulva, etc., and tested against mechanical contact such as sexual intercourse, and the purpose was achieved, with the exception of slight bleeding in 3 couples, such as severe vaginal opening atrophy and narrowing, and both husband and wife strongly recommend continuous use. I hoped. The three couples did not have any bacterial infections, and their disorders gradually healed with continuous use, and like the 94 people, they also improved and requested continued use. As we move toward an aging society, the externally applied lubricating liquid of the present invention is expected to become a daily necessity.
つぎに本発明を、実施例をあげて説明する。Next, the present invention will be explained by giving examples.
実施例(1)(ペースト状外用塗布潤滑液剤)A)1)
抗酸化剤 0.22)防腐
剤 0.23)保湿剤
2.0B)4)精製水
20.0C)5)精製水
20976)グリセリン
5.07)EDTA−2N、a
0.038〉1%乳酸
適量D)9)ハイドロキンエチルセル
ローズ 適量10)精製水
4o、0E)II)塩化リゾチーム
0.512)精製水
10.0製法
A)を加湿溶解し加湿したB)を注油し秤取したC)に
添IJD均一化する。沸騰したこの10)を攪拌し乍ら
9)を徐々に添加透明化する迄攪拌を続は完全溶解を確
認しA)〜C)の溶解液を徐々に添加し乍ら均一化させ
る。 次に完全溶解したE)を徐々に注油均−化してp
H4,0〜6.0なかんずくpH5,51’+i後に調
整し粘度20〜40ボイスなかんずく30ポイス程度に
なる様に調整し製品とする。Example (1) (paste-like externally applied lubricant) A) 1)
Antioxidants 0.22) Preservatives 0.23) Humectants
2.0B) 4) Purified water
20.0C) 5) Purified water
20976) Glycerin
5.07) EDTA-2N,a
0.038>1% lactic acid
Appropriate amount D) 9) Hydroquine ethyl cellulose Appropriate amount 10) Purified water
4o, 0E) II) Lysozyme chloride
0.512) Purified water
10.0 Manufacturing method A) is dissolved in a humidified manner, and the humidified B) is added to C), which is lubricated and weighed, and homogenized by IJD. While stirring the boiled 10), gradually add 9) and stir until the mixture becomes transparent.After confirming complete dissolution, gradually add the solutions A) to C) and homogenize. Next, the completely dissolved E) is gradually oiled and leveled, and
H4.0 to 6.0, especially pH 5.51'+i, and then adjusted to a viscosity of 20 to 40 voices, especially about 30 poices, and used as a product.
猶、潤滑作用を強調する場合と障害による治療を強調す
る場合とで塩化リゾチームの処方量を調整し製品化する
ことも可能である。However, it is also possible to commercialize products by adjusting the prescription amount of lysozyme chloride depending on whether the lubrication effect is emphasized or the treatment of disorders is emphasized.
猶、地均粘剤使用の場合にはD)項によって同様物性に
なる降調整することによって得られる。However, in the case of using a ground-leveling agent, the same physical properties can be obtained by adjusting the properties according to item D).
実施例(■)(ゼリー状外用塗布潤滑液剤)Δ)I)抗
酸化剤 0.22)防腐剤
0.23)保湿剤
2,0B)4 ン f、
Y !ム?水
20.DC>5)fη袈水
20.976)グリセリン
5.07)EDTA−2Na
O,03D)8)カーボボール940
1.19)精製水 26
゜5E)10)炭酸カリウム
0.511)グリセリン 3,
012)lit製氷 1O
6OF)13)1%乳酸
適量G)14)塩化リゾチーム
0.515>精製水 10
.0製法
A)を加熱溶解し加温したB)を注油し秤取したC)に
添加均一化しくI)とする。Example (■) (Jelly-like externally applied lubricating liquid) Δ) I) Antioxidant 0.22) Preservative 0.23) Humectant
2,0B)4 f,
Y! Mu? water
20. DC>5) fη Kesui
20.976) Glycerin
5.07) EDTA-2Na
O,03D)8) Carboball 940
1.19) Purified water 26
゜5E) 10) Potassium carbonate
0.511) Glycerin 3,
012) lit ice making 1O
6OF) 13) 1% lactic acid
Appropriate amount G) 14) Lysozyme chloride
0.515>Purified water 10
.. 0 Production method A) was heated and dissolved, and then B) was added to C), which was oiled and weighed to make it uniform.I).
次にD)の8)を秤取ホモミキサーにて攪拌中の9)中
に徐々に添加し均一な懸濁液とし次にプロペラ攪拌に切
り換えて(Nを徐々に注油し均一化する。次に均一化し
たG)を徐々に注油し続けて均一化したE)を注油均−
化する。C’に的にはpHが4〜6.0なかんず<pH
5,5t)マj後に調整をF)にて行い粘度が40〜6
0ボイスなかんずく50ポイス前後になる様に調整し製
品とする。Next, gradually add 8) of D) to 9) which is being stirred with a homomixer to make a uniform suspension. Next, switch to propeller stirring (gradually add N to make it uniform.Next Gradually continue to lubricate the homogenized G), and then lubricate the homogenized E) evenly.
become For C', the pH is 4 to 6.0, especially <pH
5,5t) After maj, adjust in F) until the viscosity is 40-6
The product is adjusted to have 0 voices, especially around 50 points.
猶剤型は実施例(1)(n)に限定されるものではない
。The suspension type is not limited to Examples (1) and (n).
特許出頭人 有限会社 東京三忠化学patent applicant Tokyo Sanchu Chemical Co., Ltd.
Claims (1)
1)の外用塗布潤滑液剤である。 b)塩化リゾチームの濃度が0.1%〜2.0%なかん
ずく0.3%〜0.7%であることを特徴とする。[Claims] a) characterized by containing lysozyme chloride (
1) is an externally applied lubricating liquid. b) characterized in that the concentration of lysozyme chloride is between 0.1% and 2.0%, in particular between 0.3% and 0.7%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61183425A JPS6341425A (en) | 1986-08-06 | 1986-08-06 | Lubricant external ointment for combined purposes of lubrication in hyposecretion of bartholin's gland and mechanical troubles thereby |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61183425A JPS6341425A (en) | 1986-08-06 | 1986-08-06 | Lubricant external ointment for combined purposes of lubrication in hyposecretion of bartholin's gland and mechanical troubles thereby |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6341425A true JPS6341425A (en) | 1988-02-22 |
Family
ID=16135551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61183425A Pending JPS6341425A (en) | 1986-08-06 | 1986-08-06 | Lubricant external ointment for combined purposes of lubrication in hyposecretion of bartholin's gland and mechanical troubles thereby |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6341425A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0396394A2 (en) † | 1989-05-03 | 1990-11-07 | DePuy International Limited | Sterilisable lubricant |
-
1986
- 1986-08-06 JP JP61183425A patent/JPS6341425A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0396394A2 (en) † | 1989-05-03 | 1990-11-07 | DePuy International Limited | Sterilisable lubricant |
EP0396394B2 (en) † | 1989-05-03 | 2000-08-16 | DePuy International Limited | Sterilisable lubricant |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2403012C2 (en) | Mucoadhesive xyloglucan-containing preparations effective in medical devices and pharmaceutical preparations | |
US11426424B2 (en) | Molecular oxygen and hyaluronic acids for topical-vaginal uses | |
RU2308951C2 (en) | Complex method for preventing vaginal dysbacteriosis (variants) | |
CN103405610A (en) | Compact-type water-soluble human lubricant, preparation method of lubricant and condom | |
US20240122842A1 (en) | System, product and method for maintaining the vaginal microbiome | |
CN112770765B (en) | Composition for preventing and/or treating urogenital mucosa | |
EP3386502A1 (en) | Synergistic combination of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae, and related pharmaceutical formulations | |
CN103405594A (en) | Water-soluble personal lubricant, preparation method thereof, and condom employing lubricant | |
JPS6341425A (en) | Lubricant external ointment for combined purposes of lubrication in hyposecretion of bartholin's gland and mechanical troubles thereby | |
RU2810844C2 (en) | Composition for use in prevention and/or treatment of pathologies of mucous membrane of genitourinary system | |
EP3496731B1 (en) | Composition for the treatment of pathologies of the urinary system | |
JPH10182435A (en) | Coating lubricating liquid for external use | |
JP2880477B2 (en) | Externally applied lubricant | |
EA042459B1 (en) | ASSOCIATION INCLUDING OXYGEN AND HYALURONIC ACID FOR TOPICAL VAGINAL APPLICATION | |
RU2188660C1 (en) | Method for treating bacterial vaginosis | |
JPH0372607B2 (en) | ||
CN105126180B (en) | A kind of medical human lubricant and preparation method thereof | |
Brink | Diseases of the pituitary body | |
Flett | Jugular Thrombosis after Tonsillitis | |
TETANUS | it'I'1i Ai} I ton.--wt | |
Lindeque | Vulvar conditions where allergy plays a role |